EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›SEPN

SEPN

Septerna, Inc.

Next earnings Aug 10, 2026 · consensus $-0.47 EPS, $16.3M rev

Last earnings +12.9% on 2026-05-11

Hold
$37.34
▲ +8.11%
$37.34▲ +255.28%
over 1Y
L $10.51EODHDH $37.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.1%
1W+8.1%
1M+25.3%
3M+56.4%
YTD+33.5%
1Y+255.3%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
D
Valuation
Fair value
Filings
Clean
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Buy

Revenue grew 4174.5% YoY; but unprofitable (net margin -106.4%).

Revenue (FY2025) $46.0M · FY2025

Septerna, Inc. shows $46.0M in FY2025 revenue (+4174.5% YoY), a -106.4% net margin, and -12.8% ROE.

Financials · annual, by fiscal year

Line itemFY23FY24FY25
Revenue$151K$1.07M$46.0M
Gross profit———
Operating income$2.08M-$80.8M-$68.3M
Net income$4.18M-$71.8M-$48.9M
Diluted EPS$0.29-$7.26-$1.10
Net margin2768.2%-6678.9%-106.4%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$1.56B
EV / EBITDA—
EV / Sales33.9
EV / FCF14.2
P / FCF15.3
PEG (trailing)—
Earnings yield-2.9%
FCF yield6.5%

Quality & risk

ROIC (est.)-14.1%
Free cash flow$110M
Total debt—
Net cash$121M
Altman Z-Score4.65 safe
Piotroski F-Score4/7

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.0%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Routine disclosure cadence — no material red flags in recent filings.
  1. 8-K Earnings results2026-05-11
  2. 10-Q Quarterly report2026-05-11
  3. DEF 14A Proxy statement2026-04-30
  4. 8-K Reg FD disclosure2026-04-13
  5. 8-K Earnings results2026-03-09
  6. 10-K Annual report2026-03-09
  7. 8-K Reg FD disclosure2026-03-02
  8. 8-K Reg FD disclosure2026-01-12
  9. 8-K Reg FD disclosure2026-01-08

Recent filings

all on EDGAR ↗
144Filing2026-06-26open ↗4Period ending 2026-06-222026-06-24open ↗144Filing2026-06-22open ↗144Filing2026-06-22open ↗4Period ending 2026-06-122026-06-16open ↗144Filing2026-06-12open ↗4Period ending 2026-06-012026-06-03open ↗4Period ending 2026-05-262026-05-28open ↗144Filing2026-05-26open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗ARSPeriod ending 2025-12-312026-04-30open ↗

Quality score

D
ValueGrowthProfitHealthMom.
ValueF
GrowthA+
ProfitabilityF
Financial healthB-
Momentum—
  • ✓Revenue growing year-over-year
  • ✗Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$46.0M
+4174.5% YoY
Net margin
-106.4%
ROE
-12.8%
P/E
—

SEC fundamentals · FY 2025

'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$46.0M+4174.5%
Net income-$48.9M+31.9%
Operating income-$68.3M+15.5%
Diluted EPS-$1.10+84.8%
Cash & equivalents$121M-49.3%
Total assets$596M+30.6%
Total liabilities$214M+486.9%
Stockholders' equity$382M-9.1%
Op.: -148.6%L/E: 0.56x

Frequently asked

Is Septerna, Inc. (SEPN) a buy?
SEPN currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 4174.5% YoY; but unprofitable (net margin -106.4%).
What is Septerna, Inc.'s quality score?
SEPN scores 48.56862745098039/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001984086, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 4:54:51 PM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 10 sales

2026-06-22
Long Daniel D.
SVP, Drug Discovery
Exercise10.5K @ $2.76$29.1K
2026-06-22
Long Daniel D.
SVP, Drug Discovery
Exercise4.47K @ $11.70$52.3K
2026-06-22
Long Daniel D.
SVP, Drug Discovery
Sell8.00K @ $35.10$281K
2026-06-22
Long Daniel D.
SVP, Drug Discovery
Sell7.00K @ $35.97$252K
2026-06-12
Shaikhly Samira
Chief People Officer
Exercise6.25K @ $11.70$73.1K
2026-06-12
Shaikhly Samira
Chief People Officer
Sell6.25K @ $35.08$219K
2026-06-01
Shaikhly Samira
Chief People Officer
Exercise4.36K @ $1.55$6.75K
2026-06-01
Shaikhly Samira
Chief People Officer
Exercise943.00 @ $2.76$2.60K
2026-06-01
Shaikhly Samira
Chief People Officer
Exercise637.00 @ $2.76$1.76K
2026-06-01
Shaikhly Samira
Chief People Officer
Sell1.70K @ $27.78$47.2K
2026-06-01
Shaikhly Samira
Chief People Officer
Sell1.35K @ $28.79$38.8K
2026-06-01
Shaikhly Samira
Chief People Officer
Sell2.89K @ $29.66$85.7K

Earnings history

beat/miss · move
2026-05-11Beat +55.3% est▼ -1.26%8-K ↗
2026-03-09Beat +7.3% est▲ +0.97%8-K ↗
2025-11-10Miss -111.1% est▼ -2.22%8-K ↗
2025-08-11Miss -163.8% est▼ -1.71%8-K ↗
2025-05-15—▼ -0.39%8-K ↗
2025-03-27—▲ +2.44%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Health Care had the best week vs. the S&P 500 on recordBullish
seekingalpha.com· 2026-06-26
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical OfficerBullish
finance.yahoo.com· 2026-06-08
Axsome Therapeutics (AXSM) Reports Q1 Loss, Beats Revenue EstimatesBullish
finance.yahoo.com· 2026-05-04
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This StockBullish
finance.yahoo.com· 2026-03-27
Septerna Reports Positive Phase 1 Data For SEP-631; Plans Phase 2 In CS UrticariaBullish
nasdaq.com· 2026-03-02
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategyBullish
globenewswire.com· 2026-03-01

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score49 vs 67
Revenue growth4174.5% vs 7.1%
Net margin-106.4% vs 10.5%
Return on equity-12.8% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 3d
Bullish
+0.17
vs typical · 3 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.